Lyme vaccine shows strong efficacy in late-stage results but misses primary endpoint

Pfizer and Valneva's Lyme disease vaccine posted 73.2% efficacy starting 28 days after the fourth dose in a late-stage trial, but the study missed its primary endpoint under the worst-case scenario (15.8% efficacy in the initial analysis); a second analysis showed 74.8% efficacy, leading to plans for regulatory submissions, with no Lyme vaccine currently approved.